AAPA Members, login to view FREE Full Text for all articles. Not a member? Join today!

Institutional members access full text with Ovid®

Share this article on:

Combined angiotensin receptor and neprilysin inhibition therapy for heart failure

Lu, Becky N., PharmD; Davis, Lindsay E., PharmD, BCPS

Journal of the American Academy of PAs: July 2018 - Volume 31 - Issue 7 - p 35–37
doi: 10.1097/01.JAA.0000534982.53989.c2
Review Article

ABSTRACT The FDA has approved sacubitril/valsartan, an angiotensin-receptor-neprilysin inhibitor, for the treatment of chronic symptomatic heart failure (stage C) in patients with a left ventricular ejection fraction of 35% or less. This article discusses results from a major clinical trial, PARADIGM-HF, and the role of this new drug in heart failure treatment.

At the time this article was written, Becky N. Lu was a student at Midwestern University College of Pharmacy in Glendale, Ariz. Lindsay E. Davis is an associate professor at Midwestern University. The authors have disclosed no potential conflicts of interest, financial or otherwise.

Copyright © 2018 American Academy of Physician Assistants
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website